FDA and FTC warn CBD Social over website claims that CBD products prevent or treat COVID-19.
What happened
FDA reviewed the website on February 17, 2022, and FTC reviewed it on March 15, 2022. The agencies found CBD products offered for sale with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says this makes the products unapproved new drugs and misbranded drugs.
What FDA found
The website claims CBD products mitigate, prevent, treat, diagnose, or cure COVID-19, so FDA treats them as unapproved new drugs.
FD&C Act section 505(a), 21 U.S.C. § 355(a)The products are misbranded, meaning their labeling is false or misleading, because the labeling includes misleading COVID-19 claims.
FD&C Act section 502, 21 U.S.C. § 352The company is prohibited from introducing these products into interstate commerce.
FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)FTC says the company advertised that its products prevent, treat, or cure disease without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.FTC says deceptive COVID-19 treatment, cure, prevention, or mitigation claims can lead to civil penalties under the COVID-19 Consumer Protection Act.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA tells CBD Social to take immediate action to stop selling unapproved products for COVID-19 and, within 48 hours, to email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and related documentation. FDA also tells the company to review its websites, labels, and promotional materials to remove misleading COVID-19 claims.
Who should pay attention
- CBD brands and retailers that make health claims
- companies selling COVID-19-related products online
- marketers of unapproved drugs or supplements
This is a summary. Read the original letter on fda.gov.